Physician profile
Guillermo Bohm
NPI 1437157724
$5,007.24
in general payments reported to CMS, 2019-2025
39 companies · $260 in 2025
The $260 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,288 · 2020: $447 · 2023: $269 · 2024: $1,743 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,270 · Education: $2.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,270.42 |
| Education | $2.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $548.15 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $451.62 | 2019-2025 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $388.29 | 2023-2024 | |
| Radius Health, INC. | $381.09 | 2019-2023 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $364.83 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $322.56 | 2019-2020 | |
| Corcept Therapeutics | $302.08 | 2020-2025 | Korlym |
| Mannkind Corporation | $257.01 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $229.56 | 2019-2024 | |
| Xeris Pharmaceuticals, INC. | $215.78 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Dexcom, INC. | $185.33 | 2019-2025 | Dexcom G6 Transmitter |
| Madrigal Pharmaceuticals | $160.66 | 2024 | Rezdiffra, Resmetirom |
| Antares Pharma, INC. | $149.44 | 2019-2025 | Xyosted |
| Regeneron Healthcare Solutions, INC. | $134.79 | 2019 | |
| Insulet Corporation | $73.48 | 2019-2023 | Omnipod |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $69.86 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Abbvie INC. | $69.20 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $65.51 | 2024-2025 | Strensiq |
| Merck Sharp & Dohme LLC | $60.41 | 2019-2020 | |
| Recordati_rare_diseases_inc. | $49.80 | 2023-2024 | Signifor Lar, Isturisa |
| Kowa Pharmaceuticals America, INC. | $48.99 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $44.58 | 2024 | |
| Medtronic Minimed, INC. | $42.58 | 2019 | |
| Halozyme INC | $40.23 | 2023 | |
| Abbott Laboratories | $38.90 | 2024-2025 | Freestyle Libre 3 |
| Almatica Pharma LLC | $37.07 | 2024 | Teriparatide |
| Amgen INC. | $35.68 | 2019-2024 | Repatha |
| Valeritas, INC. | $32.18 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.22 | 2019-2020 | |
| Kyowa Kirin, INC. | $25.23 | 2024 | Crysvita |
| Opko Pharmaceuticals, LLC | $23.54 | 2024 | Rayaldee |
| Verity Pharmaceuticals INC. | $22.88 | 2024 | Tlando |
| Ultragenyx Pharmaceutical INC. | $22.65 | 2024 | Crysvita |
| Esperion Therapeutics, INC. | $17.88 | 2024 | Nexletol |
| Companion Medical, INC. | $17.02 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $15.97 | 2019 | |
| Amneal Pharmaceuticals LLC | $15.47 | 2019 | |
| Ibsa Pharma INC. | $12.38 | 2019 | |
| Kvk-Tech, INC. | $4.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guillermo Bohm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.